Economic burden following allogeneic hematopoietic stem cell transplant in patients with diffuse large B-cell lymphoma

Richard T. Maziarz, Yanni Hao, Annie Guerin, Genevieve Gauthier, Marjolaine Gauthier-Loiselle, Simu K. Thomas, Lamis Eldjerou

Research output: Contribution to journalArticle

8 Scopus citations

Abstract

This study describes short-term and long-term healthcare resource utilization (HRU) and costs following an allogeneic hematopoietic stem cell transplant (HSCT) in adult patients with diffuse large B-cell lymphoma (DLBCL) in a real-world setting. Among 101 patients with DLBCL receiving an allogeneic HSCT, HRU and direct healthcare costs for up to three years after the allogeneic HSCT are described. HRU and costs were substantial, with the most intensive HRU and highest healthcare costs observed during the first year after HSCT (38 inpatient days; 68 days with office visits and average healthcare costs of $455,741). Although HRU and costs decreased over time, they remained high even in the third year after HSCT (four inpatient days; 27 days with office visits and average healthcare costs of $72,957). Overall, this study showed that the economic burden following an allogeneic HSCT in DLBCL patients is significant.

Original languageEnglish (US)
Pages (from-to)1133-1142
Number of pages10
JournalLeukemia and Lymphoma
Volume59
Issue number5
DOIs
StatePublished - May 4 2018

Keywords

  • Diffuse large B-cell lymphoma
  • allogeneic hematopoietic stem cell transplant
  • economic burden
  • healthcare costs
  • healthcare resource utilization

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Economic burden following allogeneic hematopoietic stem cell transplant in patients with diffuse large B-cell lymphoma'. Together they form a unique fingerprint.

  • Cite this